Virtual Study Groups

Estimated Time To Complete Activity:    3 hours

Albert Einstein College of Medicine of Yeshiva University and AXIS Medical Education, Inc. cordially invite participants of the CME-certified virtual grand rounds activity entitled, ”Optimizing Management of Chronic Myelogenous Leukemia: Therapeutic Strategies Making a Difference,” to participate in the follow-up Virtual Study Groups. This series of six CME-certified Virtual Study Groups will focus on the latest clinical research, emerging data, and strategies for improving outcomes for patients with chronic myelogenous leukemia, and allow participants to interact with expert faculty on discussion points and cases related to the following topics:

  • Newly diagnosed chronic-phase CML: A comparison of tyrosine kinase inhibitors
  • Safety profiles of first- and second-generation tyrosine kinase inhibitors
  • Monitoring and mutation testing in patients with CML
  • Response to CML treatment failure due to toxicity or resistance
  • CML therapy adherence and the effects of poor compliance
  • Diagnosis and treatment of advanced-phase CML


The comprehensive content of this program will emphasize and reinforce a multidisciplinary team-based approach and will provide insight into the optimal therapeutic approaches for the treatment of patients with CML.

Fee Statement
There is no fee for this educational activity.

Target Audience
This activity is intended for hematologists/oncologists who treat or manage patients with CML. The secondary audience is oncology nurses, oncology nurse practitioners, physician assistants, and oncology pharmacists.

Learning Objectives
At the conclusion of this activity, participants should be better able to:

  • Apply mutational testing strategies to inform optimal treatment and monitoring of CML patients
  • Explain and interpret molecular response criteria in CML
  • Identify and define what constitutes poor response, resistant disease, disease intolerance and strategies to overcome these challenges
  • Apply evidence-based updates for selecting optimal treatment for first-line and second- line therapy, including when to consider combination and maintenance options
  • Implement best-practice recommendations for improving patient compliance to oral therapy
  • Evaluate recent trial data on current and novel agents and incorporate newly available treatment options for patients with CML
  • Compare and contrast the safety, tolerability, and clinical outcomes of all options now available for the treatment of patients with CML


Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Albert Einstein College of Medicine of Yeshiva University, Montefiore Medical Center and AXIS Medical Education. Albert Einstein College of Medicine of Yeshiva University is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Albert Einstein College of Medicine of Yeshiva University designates this performance activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

A certificate will be issued only upon receipt of a completed activity evaluation form and will be mailed to you within 3 weeks.

Disclosure of Conflicts of Interest
The “Conflict of Interest Disclosure Policy” of Albert Einstein College of Medicine of Yeshiva University requires that faculty participating in any CME activity disclose to the audience any relationship(s) with a pharmaceutical, product, or device company.  Any presenter whose disclosed relationships prove to create a conflict of interest with regard to their contribution to the activity will not be permitted to present.

The Albert Einstein College of Medicine of Yeshiva University also requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.” Albert Einstein College of Medicine of Yeshiva University, CCME staff, has no conflicts of interest with commercial interests related directly or indirectly to this educational activity.

Technical Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 5.0+ for Mac OSX 10.5 and above

For video playback, install the latest version of Flash or Quicktime.

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

VSG Dates
Virtual Study Group 1
:
Newly Diagnosed Chronic-Phase CML: A Comparison of Tyrosine Kinase Inhibitors

Virtual Study Group 2:
Safety Profiles of First- and Second-Generation Tyrosine Kinase Inhibitors

Wednesday, October 22, 2014: 5:00 – 6:00pm ET
Speakers:

Jerald P. Radich, MD
Fred Hutchinson Cancer Research Center
Seattle, Washington

Neil P. Shah, MD, PhD
University of California, San Francisco
San Francisco, CA

Virtual Study Group 3:
Monitoring and Mutation Testing in Patients with CML

Wednesday, November 12, 2014: 5:00 – 5:30pm ET
Speakers:      

Jerald P. Radich, MD
Fred Hutchinson Cancer Research Center
Seattle, Washington

Michael W.N. Deininger, MD, PhD
University of Utah
Huntsman Cancer Institute
Salt Lake City, UT

Virtual Study Group 4:
Response to CML Treatment Failure Due to Toxicity or Resistance

Thursday, January 8, 2015: 5:00 – 5:30pm ET
Speakers:

Jerald P. Radich, MD
Fred Hutchinson Cancer Research Center
Seattle, Washington

Harry P. Erba, MD, PhD
University of Alabama at Birmingham
Birmingham, AL

Virtual Study Group 5:
CML Therapy Adherence and the Effects of Poor Compliance

Thursday, February 5, 2015: 5:00 – 5:30pm ET
Speakers:

Jerald P. Radich, MD
Fred Hutchinson Cancer Research Center
Seattle, Washington

Harry P. Erba, MD, PhD
University of Alabama at Birmingham
Birmingham, AL

Virtual Study Group 6:
Diagnosis and Treatment of Advanced-Phase CML

  1. Thursday, March 26, 2015: 5:00 – 5:30pm ET 
  2. Speakers:
  3. Jerald P. Radich, MD
  4. Fred Hutchinson Cancer Research Center
  5. Seattle, Washington
  6. Jorge E. Cortes, MD
  7. The University of Texas MD Anderson Cancer Center
  8. Houston, TX

Provider
Jointly provided by

This activity is supported by an educational grant from Bristol-Myers Squibb Company.